Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
The small molecule Chicago Sky Blue promotes heart repair following myocardial infarction in mice
Oren Yifa, … , Nenad Bursac, Eldad Tzahor
Oren Yifa, … , Nenad Bursac, Eldad Tzahor
Published November 14, 2019
Citation Information: JCI Insight. 2019;4(22):e128025. https://doi.org/10.1172/jci.insight.128025.
View: Text | PDF
Research Article Cardiology Therapeutics

The small molecule Chicago Sky Blue promotes heart repair following myocardial infarction in mice

  • Text
  • PDF
Abstract

The adult mammalian heart regenerates poorly after injury and, as a result, ischemic heart diseases are among the leading causes of death worldwide. The recovery of the injured heart is dependent on orchestrated repair processes including inflammation, fibrosis, cardiomyocyte survival, proliferation, and contraction properties that could be modulated in patients. In this work we designed an automated high-throughput screening system for small molecules that induce cardiomyocyte proliferation in vitro and identified the small molecule Chicago Sky Blue 6B (CSB). Following induced myocardial infarction, CSB treatment reduced scar size and improved heart function of adult mice. Mechanistically, we show that although initially identified using in vitro screening for cardiomyocyte proliferation, in the adult mouse CSB promotes heart repair through (i) inhibition of CaMKII signaling, which improves cardiomyocyte contractility; and (ii) inhibition of neutrophil and macrophage activation, which attenuates the acute inflammatory response, thereby contributing to reduced scarring. In summary, we identified CSB as a potential therapeutic agent that enhances cardiac repair and function by suppressing postinjury detrimental processes, with no evidence for cardiomyocyte renewal.

Authors

Oren Yifa, Karen Weisinger, Elad Bassat, Hanjun Li, David Kain, Haim Barr, Noga Kozer, Alexander Genzelinakh, Dana Rajchman, Tamar Eigler, Kfir Baruch Umansky, Daria Lendengolts, Ori Brener, Nenad Bursac, Eldad Tzahor

×

Figure 6

CSB inhibits immune cell activation but not recruitment.

Options: View larger image (or click on image) Download as PowerPoint
CSB inhibits immune cell activation but not recruitment.
Twelve-week-old...
Twelve-week-old mice underwent MI and were injected with CSB or PBS. The first injection was i.m. into the myocardium immediately after injury. Additional i.v. injections were given 2, 4, and 6 days after MI. Hearts were harvested 1, 4, or 8 days after MI and ELISA was performed. All tested cytokines are presented. (A) Cytokine levels show general attenuation of the inflammatory response after CSB treatment. (B) The level of the 3 tested chemokine (C-C motif) ligands (CCLs) is not inhibited by CSB 4 days after MI. (C) Average change in the levels of all cytokines except CCLs (cytokines in panel A) relative to uninjured mice. For each treatment at each time point n = 13, mean ± SEM, paired 2-tailed Student’s t test. *P < 0.05, ****P < 0.0001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts